Business Wire

Tanium Converge Travels to London and Paris

13.4.2023 10:00:00 EEST | Business Wire | Press release

Share

Tanium, the industry’s only provider of converged endpoint management (XEM), today announced the beginning of the Converge World Tour 2023, a six-city series of its global user conference. The kickoff event in London will be held Tuesday, 18th April, at the London Landmark Hotel, with a show at the Campus Cyber, Paris to follow on Thursday where Tanium will showcase its innovation spotlight, including its product roadmap and future enhancements to the XEM platform.

Converge is Tanium’s flagship event that brings together industry specialists, peers, and partners to share strategies for leveraging converged endpoint management (XEM) to improve organizational cybersecurity readiness and response. There’s no better opportunity for IT and security practitioners to discover new ways of driving value to their boards and accelerating business initiatives than to gain outside perspectives and hear first-hand experiences from those on the frontline of the cyber landscape.

“Tanium’s commitment is first, last, and always to our customers, and we are grateful to have such a strong and extensive partner ecosystem that is equally committed to maximizing the value our customers achieve from their investments in Tanium,” said Steve Daheb, chief marketing officer at Tanium. “Join us in Paris and London to see why Forrester reports Tanium driving ROI of more than 200% for customers, why eight of top 10 global financial institutions and seven of the top 10 global retailers trust Tanium to maximize their ROI and simplify their technology environments while defending their organizations against emerging threats and expanding their knowledge of managing risk, securing technology, and unlocking innovation at scale from a single intuitive platform.”

Join Tanium for a dynamic keynote experience, featuring top executives and industry experts who will enable you to:

  • Glimpse into the future with Tanium—including the global unveiling of a new offering designed to improve overall work productivity, increase employee satisfaction, and lower IT support costs
  • Understand the use and benefits of XEM with category creator Steve Daheb
  • Gain insights from an intimate fireside chat with customer success champion Charles Ross
  • Explore the many ways Microsoft and Tanium work better together to improve cyber resilience with partner facilitator Mike Fiorina
  • Get a firsthand look at real customer successes with a panel featuring Aviva and Fraser’s Group and partner enablement executive Todd Palmer
  • Participate in peer-based breakout sessions across executive-, technical-, and partner-focused tracks

WHO : IT and security professionals from across Europe; Tanium’s newly appointed CEO, Dan Streetman, and members of his executive team; Forrester analyst Andrew Hewitt; Frasers Group’s Matthew Wilmot; Aviva’s Marc Hasketh-Boston; and Tanium customers and partners that include EY, PwC, Armadillo Managed Services, Computacenter, SCC, EndpointX, Pointwire, BlueTrusty, Capgemini, Cegedim, DOUNYX, EY, I-TRACING, Orange Cyberdefense, and more

WHAT : Tanium Converge London and Tanium Converge Paris, featuring spotlights on current trends, industry best practices, expert-led sessions, breakout discussions, and hands-on labs

WHER E: The Landmark London Hotel and the Campus Cyber in Paris–La Defense

WHEN : Tuesday, 18th April 2023 (London) and Thursday, 20th April (Paris)

HOW : The shows are sold out, but you can still register to secure your place on the waitlist or join us for mainstage public sessions on demand by signing up for the London show or the Paris event. We look forward to seeing you there!

About Tanium

Tanium, the industry’s only provider of converged endpoint management (XEM), is the reference platform of choice to manage complex security and technology environments. Only Tanium unifies teams and workflows and protects every endpoint from cyber threats by integrating IT, Compliance, Security, and Risk into a single platform that delivers comprehensive visibility across devices, a unified set of controls, and a common taxonomy for a single shared purpose: to protect critical information and infrastructure at scale. Tanium has been named to the Forbes Cloud 100 list for seven consecutive years and ranks on Fortune’s list of the Best Large Workplaces in Technology. In fact, more than half of the Fortune 100 and the U.S. armed forces trust Tanium to protect people; defend data; secure systems; and see and control every endpoint, team, and workflow everywhere. That’s the power of certainty. Visit www.tanium.com and follow us on LinkedIn and Twitter.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Lindsey Lockhart
Tanium PR
press@tanium.com
+ 1 214.562.1521

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye